Movement Disorders (revue) - Checkpoint (Ncbi)

Index « Mesh.i » - entrée « Receptors, Dopamine »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Receptors, Cholinergic < Receptors, Dopamine < Receptors, Dopamine D1  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 72.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000103 (1999) O. Rascol [France]L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
000113 (1999) W J Weiner [États-Unis]The initial treatment of Parkinson's disease should begin with levodopa.
000119 (1999) P. Barbanti [Italie] ; G. Fabbrini ; A. Ricci ; R. Cerbo ; E. Bronzetti ; B. Caronti ; C. Calderaro ; L. Felici ; F. Stocchi ; G. Meco ; F. Amenta ; G L LenziIncreased expression of dopamine receptors on lymphocytes in Parkinson's disease.
000183 (2000) L V Metman ; S. Konitsiotis ; T N ChasePathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
000205 (2000) W G Ondo [États-Unis] ; Y. He ; S. Rajasekaran ; W D LeClinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome.
000268 (2000) D A Di Monte [États-Unis] ; A. Mccormack ; G. Petzinger ; A M Janson ; M. Quik ; W J LangstonRelationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
000B15 (2003) Juha-Matti Savola [Finlande] ; Michael Hill ; Mia Engstrom ; Hannele Merivuori ; Siegfried Wurster ; Steven G. Mcguire ; Susan H. Fox ; Alan R. Crossman ; Jonathan M. BrotchieFipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
000B37 (1992) M R Luquin ; O. Scipioni ; J. Vaamonde ; O. Gershanik ; J A ObesoLevodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
000C15 (2003) Stephen J. KishWhat is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
000F17 (1992) J. Schwarz [Allemagne] ; K. Tatsch ; T. Vogl ; C M Kirsch ; C. Trenkwalder ; G. Arnold ; T. Gasser ; W H OertelMarked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
000F20 (1992) M. Emre [Suisse] ; U K Rinne ; A. Rascol ; A. Lees ; Yves Agid [France] ; X. LatasteEffects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson disease.
000F25 (2004) C Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno ; Alberto Albanese ; Ubaldo Bonuccelli ; U. Bonucelli ; Philip Damier ; Justo De Yebenes ; Oscar Gershanik ; Mark Guttman ; F. Grandas ; Mark Hallett ; Ole Hornykiewicz ; Peter Jenner ; R. Katzenschlager ; William J. Langston ; Peter Lewitt ; Eldad Melamed ; M A Mena ; P P Michel ; Catherine Mytilineou ; Jose A. Obeso ; Werner Poewe [Autriche] ; Niall Quinn ; R. Raisman-Vozari ; Ali H. Rajput ; Olivier Rascol ; Christina Sampaio ; Fabrizio StocchiLevodopa in the treatment of Parkinson's disease: current controversies.
001035 (2004) Ida Rissling [Allemagne] ; Frank Geller ; Oliver Bandmann ; Karim Stiasny-Kolster ; Yvonne Körner ; Charlotte Meindorfner ; Hans-Peter Krüger ; Wolfgang H. Oertel ; J Carsten MöllerDopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks".
001457 (1992) D. Bravi [États-Unis] ; J J Anderson ; F. Dagani ; T L Davis ; R. Ferrari ; M. Gillespie ; T N ChaseEffect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
001485 (2006) Daniela Perani ; Valentina Garibotto ; George M. Hadjigeorgiou ; Dimitra Papadimitriou ; Ferruccio Fazio ; Alexandros PapadimitriouPositron emission tomography changes in PARK1 mutation.
001548 (2006) Judith A. Strong [États-Unis] ; Arif Dalvi ; Fredy J. Revilla ; Alok Sahay ; Frederick J. Samaha ; Jeffrey A. Welge ; Jianhua Gong ; Maureen Gartner ; Xia Yue ; Lei YuGenotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
001785 (1991) G. Pezzoli [Italie] ; A. Zecchinelli ; S. Ricciardi ; R E Burke ; S. Fahn ; G. Scarlato ; A. CarenziIntraventricular infusion of epidermal growth factor restores dopaminergic pathway in hemiparkinsonian rats.
001C63 (2007) Naomi M. Warren [Royaume-Uni] ; Margaret A. Piggott ; Elizabeth Greally ; Michelle Lake ; Andrew J. Lees ; David J. BurnBasal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy.
001D03 (2007) Richard P. Allen [États-Unis] ; Christopher J. EarleyThe role of iron in restless legs syndrome.
002017 (2007) Eldad Melamed [Israël] ; Ilan Ziv ; Ruth DjaldettiManagement of motor complications in advanced Parkinson's disease.
002306 (2008) Anthony A. Grace [États-Unis]Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Receptors, Dopamine" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Receptors, Dopamine" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Receptors, Dopamine
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024